Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 6, 2025; 13(16): 101665
Published online Jun 6, 2025. doi: 10.12998/wjcc.v13.i16.101665
Published online Jun 6, 2025. doi: 10.12998/wjcc.v13.i16.101665
Metastatic pancreatic cancer with activating BRAF V600E mutations: A case report
Fang Li, Feng Shen, Department of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, Fujian Province, China
Fang Li, Feng Shen, Xiamen Clinical Research Center for Cancer, Xiamen 361015, Fujian Province, China
Fang Li, Feng Shen, Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province, Xiamen 361015, Fujian Province, China
Author contributions: LI F contributed to manuscript writing and editing, and data collection; Shen F contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Supported by Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province
Informed consent statement: Informed written consent was obtained from the patient’ parent for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Feng Shen, Doctor, Department of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, No. 668 Jinhu Road, Huli District, Xiamen 361015, Fujian Province, China. shen.feng@zs-hospital.sh.cn
Received: September 25, 2024
Revised: December 6, 2024
Accepted: January 11, 2025
Published online: June 6, 2025
Processing time: 137 Days and 18.1 Hours
Revised: December 6, 2024
Accepted: January 11, 2025
Published online: June 6, 2025
Processing time: 137 Days and 18.1 Hours
Core Tip
Core Tip: Pancreatic cancer (PC) is an extremely aggressive malignancy, characterized by a 5-year survival rate of merely 11% and is highly resistant to chemotherapy, radiotherapy and immunotherapy. PC is largely defined by core driver gene mutations. BRAF mutations are rare, but important because of the availability of targeted drugs. We report a rare case of PC with a high tumor burden with BRAF V600E mutation. Despite the use of chemotherapy and targeted therapy, the patient’s outcome remained poor. This case highlights the significance of molecular profiling in patients with pancreatic tumors, especially in young patients with aggressive characteristics.